Instructions | Rate of interest w.e.f. 01.10.2018 to 31.12.2018 | Rate of interest w.e.f. 01.01.2019 to 31.03.2019 | Compounding Frequency* |
Saving Deposit | 4.0 | 4.0 | Annually |
1 Year Time Deposit | 6.9 | 7.0 | Quarterly |
2 Year Time Deposit | 7.0 | Quarterly | |
3 Year Time Deposit | 7.2 | Quarterly | |
5 Year Time Deposit | 7.8 | 7.8 | Quarterly |
5 Year Recurring Deposit | 7.3 | 7.3 | Quarterly |
5 Year Senior Citizen Savings Scheme | 8.7 | 8.7 | Quarterly and Paid |
5 Year Monthly Income Account | 7.7 | 7.7 | Monthly and paid |
5 Year National Savings Certificate | 8.0 | 8.0 | Annually |
Publilc Provident Fund Scheme | 8.0 | 8.0 | Annually |
Kisan Vikas Patra | 7.7 (will mature in 112 months) | 7.7 (will mature in 112 months) | Annually |
Sukanya Samriddhi Account Scheme | 8.5 | 8.5 | Annually |
Date | Article |
---|---|
Jul 30, 2018 | Nektar Therapeutics Announces New Drug Application for NKTR-181 Accepted for Review by FDA |
May 31, 2018 | Nektar Therapeutics Announces Submission of a New Drug Application to the U.S. FDA for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy |
Jul 18, 2017 | Nektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain |
Sep 27, 2013 | Nektar Phase II Trial for NKTR-181 Misses Primary Endpoint |
Jun 19, 2013 | Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181 |
Jun 7, 2012 | Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain |
Feb 27, 2012 | Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting |
Sep 22, 2011 | Nektar Presents Positive Data for Novel Opioid Analgesic, NKTR-181, at the 2011 American Academy of Pain Management Annual Meeting |
Jun 7, 2011 | Data from Phase 1 Study of NKTR-181 Demonstrate Proof-of-Concept for Nektar's Novel Opioid Analgesic Candidate |
Oct 20, 2010 | Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010 |